Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 19/20 | 0.78 |
| ▸ | EGFR | P00533 | 13/20 | 0.78 |
| ▸ | ABL1 | P00519 | 9/20 | 0.78 |
| ▸ | ABL2 | P42684 | 9/20 | 0.78 |
| ▸ | CDK1 | P06493 | 7/20 | 0.78 |
| ▸ | KDR | P35968 | 6/20 | 0.78 |
| ▸ | CSK | P41240 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7847551 | 0.90 | SRC (0.91) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL31061695 | 0.88 | SRC (1.00) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL5936176 | 0.88 | SRC (1.00) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL20351594 | 0.87 | SRC (0.86) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL7845787 | 0.86 | SRC (0.84) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL7835361 | 0.85 | SRC (1.00) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL7842356 | 0.85 | SRC (0.82) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL7833880 | 0.84 | SRC (0.75) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL7847946 | 0.84 | SRC (0.80) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL7847078 | 0.83 | SRC (0.82) | SRCEGFRABL1ABL2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030016-B2 | Heterocyclic compounds useful as PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-9546165-B2 | Heterocyclic compounds useful as PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160331756-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-11-17 | — | — | US | disclosed |
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | SRC 1505/4885EGFR 2844/4885ABL1 1906/4885 |
| US-10030016-B2 | Heterocyclic compounds useful as PDK1 inhibitors | PDK1, PDK2, PDK3 | SRC 1505/4885EGFR 2844/4885ABL1 1906/4885 |
| US-20160331756-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | SRC 1505/4885EGFR 2844/4885ABL1 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.